VIM and posterior cortical atrophy: Notably, an ongoing neoadjuvant Phase 2 study including patients with PCa is comparing the effects of ADT with or without chemotherapeutic agents against SRC or MEK (degarelix, enzalutamide, trametinib, or dasatinib), by evaluating the inhibition of mesenchymal markers N-cadherin and vimentin (NCT01990196).